Celcuity Inc. (CELC) SEC Filings & Earnings Calls

Transition risk: Company moving to commercial stage after first FDA approval; board appointment aims to strengthen financial oversight but execution risk remains.

“On the heels of our first FDA approval for REVTORPYK™, we are pleased to welcome David to our Board of Directors as we transition into a commercial-stage company.” · word for word

Commercial execution risk for a new oncology product launch.

“First commercial launch for Celcuity; requires physician adoption and payer coverage.”

Safety profile includes stomatitis, rash, and hyperglycemia which may limit adoption.

“Stomatitis occurred in 72% of patients in triplet arm; Grade 3 events in 22%.”

Regulatory approval risk for sNDA; FDA may require additional data or have safety concerns (stomatitis, rash).

“IMPORTANT SAFETY INFORMATION includes warnings for stomatitis (72% incidence with triplet, 58% with doublet) and dermatologic reactions (30% rash).”

No revenue yet; reliance on successful commercial launch

“We have not generated any revenue from product sales or other sources to date, and we continue to incur significant operating and other expenses related to our ongoing operations.” · word for word

High cash burn rate

“Net cash used in operating activities was $110.5 million during the six months ended June 30, 2026.” · word for word

Dependence on single product (gedatolisib)

“We are a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK TM (gedatolisib).” · word for word

No revenue yet; company is pre-commercial with significant R&D and SG&A expenses.

“No revenue reported in the filing; focus on clinical and regulatory milestones.”

Convertible note offering increases debt and potential dilution.

“Completed issuance of $575.0 million convertible note offering, with net proceeds of $557.2 million” · word for word

Key investor reduces stake and caps ownership

“the Reporting Persons beneficially own less than 10% of the outstanding Common Stock, are not affiliates of the Issuer, and hold the securities of the Issuer for investment purposes and not with the purpose or effect of changing or influencing control of the Issuer.” · word for word

Key investor reduces stake and caps ownership

“the Reporting Persons beneficially own less than 10% of the outstanding Common Stock, are not affiliates of the Issuer, and hold the securities of the Issuer for investment purposes and not with the purpose or effect of changing or influencing control of the Issuer.” · word for word

Commercial execution risk; market acceptance and competition.

“The Company anticipates commercial launch of REVTORPYK in late Q3 2026.” · word for word

Potential dilution from conversion of notes; interest rate is low but conversion could increase share count.

“initial conversion rate of 8.0302 shares of the Company’s common stock... per $1,000 principal amount of the Notes”

Pre-revenue clinical-stage company with no approved products

“We have not generated any revenue from product sales or other sources to date, and we continue to incur significant research and development and other expenses related to our ongoing operations.” · word for word

Dependence on FDA approval and commercial launch success

“If we obtain FDA approval to market gedatolisib, we expect to generate revenue from sales of the drug commencing in the second half of 2026.” · word for word

Significant operating cash burn and reliance on financing

“Net cash used in operating activities was $55.1 million during the three months ended March 31, 2026” · word for word

Pre-revenue biotech with increasing net loss and reliance on successful FDA approval and commercial launch.

“Net loss $52.8M, no revenue, R&D $33.1M”

Pre-revenue clinical-stage company with no product sales

“We have not generated any revenue from product sales or other sources to date, and we continue to incur significant research and development and other expenses related to our ongoing operations.” · word for word

Significant net losses and negative cash flow

“Net Loss (thousands): 2025 $(177,042), 2024 $(111,779), 2023 $(63,779)”

High dilution from equity compensation

“Total dilution prior to approval of the 2026 Plan 18.2%” · word for word

Key man risk - CEO and CSO are brothers-in-law

“Dr. Laing, our Chief Science Officer and a director, is a brother-in-law of Mr. Sullivan, the Chairman of our Board and Chief Executive Officer.” · word for word

Dependence on stock price for executive compensation value

“The CAP calculation is impacted by the proportion of compensation being delivered in the form of equity awards and reflects that the market price of our common stock increased by approximately 612% from December 31, 2022, to December 31, 2025.” · word for word

FDA approval uncertainty

“Disruptions at the FDA and other government agencies from funding cuts, personnel losses, leadership changes, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which wo” · word for word

Dilution risk

“Since December 2023, we have issued 6,478,782 shares of common stock pursuant to equity financing arrangements, including pursuant to our Open Market Sale Agreement SM with Jefferies LLC, as agent, pursuant to which we may currently offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $4” · word for word

No approved products / pre-revenue

“If we receive FDA approval and launch gedatolisib in the U.S., we expect to be subject to comprehensive state privacy laws.” · word for word

Clinical trial failure pressure for PIK3CA mutant cohort; regulatory approval risk.

“Topline results from PIK3CA mutant cohort expected Q2 2026; FDA approval not guaranteed.”

Dilution risk from warrant exercise

“The Funds hold 6,147,787 prefunded warrants exercisable at $0.001 per share, which if exercised would increase share count.”

Dilution risk from warrant exercise

“The Funds hold 6,147,787 prefunded warrants exercisable at $0.001 per share, which if exercised would increase share count.”

Celcuity is a clinical-stage biotech with no approved products; gedatolisib approval and launch are subject to regulatory and commercial risks

“Celcuity is a clinical-stage biotechnology company; potential approval and launch of gedatolisib later this year” · word for word

Regulatory approval risk; NDA review outcome uncertain despite RTOR program.

“Forward-looking statements note risks including unforeseen delays in NDA review and ability to obtain regulatory approvals.”

Dependence on gedatolisib regulatory approval and commercial success

“Our business is dependent on the success of CAN-2409, CAN-3110 and any other product candidates that we advance into the clinic.”

Significant operating losses and need for additional funding

“We have incurred losses in each period since our inception in 2012.”

Clinical trial and regulatory risks for gedatolisib

“Our preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval, and commercialization.”

Clinical trial failure risk for PIK3CA mutant cohort and other pipeline assets.

“Topline data for PIK3CA mutant cohort not yet available; Phase 1b mCRPC data early stage.”

Regulatory approval uncertainty for gedatolisib NDA.

“NDA submission on track but FDA approval not guaranteed.”